Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Departments of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
Am J Pathol. 2021 Dec;191(12):2064-2071. doi: 10.1016/j.ajpath.2021.08.009. Epub 2021 Sep 8.
Current understanding of coronavirus disease 2019 (COVID-19) pathophysiology is limited by disease heterogeneity, complexity, and a paucity of studies assessing patient tissues with advanced molecular tools. Rapid autopsy tissues were evaluated using multiscale, next-generation RNA-sequencing methods (bulk, single-nuclei, and spatial transcriptomics) to provide unprecedented molecular resolution of COVID-19-induced damage. Comparison of infected/uninfected tissues revealed four major regulatory pathways. Effectors within these pathways could constitute novel therapeutic targets, including the complement receptor C3AR1, calcitonin receptor-like receptor, or decorin. Single-nuclei RNA sequencing of olfactory bulb and prefrontal cortex highlighted remarkable diversity of coronavirus receptors. Angiotensin-converting enzyme 2 was rarely expressed, whereas basigin showed diffuse expression, and alanyl aminopeptidase, membrane, was associated with vascular/mesenchymal cell types. Comparison of lung and lymph node tissues from patients with different symptoms (one had died after a month-long hospitalization with multiorgan involvement, and the other had died after a few days of respiratory symptoms) with digital spatial profiling resulted in distinct molecular phenotypes. Evaluation of COVID-19 rapid autopsy tissues with advanced molecular techniques can identify pathways and effectors, map diverse receptors at the single-cell level, and help dissect differences driving diverging clinical courses among individual patients. Extension of this approach to larger data sets will substantially advance the understanding of the mechanisms behind COVID-19 pathophysiology.
目前对 2019 年冠状病毒病(COVID-19)病理生理学的认识受到疾病异质性、复杂性以及缺乏使用先进分子工具评估患者组织的研究的限制。使用多尺度、下一代 RNA 测序方法(批量、单核和空间转录组学)对快速尸检组织进行评估,为 COVID-19 诱导的损伤提供了前所未有的分子分辨率。比较感染/未感染的组织揭示了四个主要的调控途径。这些途径中的效应物可以构成新的治疗靶点,包括补体受体 C3AR1、降钙素受体样受体或 decorin。嗅球和前额叶皮层的单核 RNA 测序突出了冠状病毒受体的显著多样性。血管紧张素转换酶 2 表达很少,而 basigin 则广泛表达,丙氨酰氨基肽酶、膜与血管/间充质细胞类型相关。对具有不同症状(一名患者在多器官受累的长达一个月的住院治疗后死亡,另一名患者在几天的呼吸症状后死亡)的患者的肺和淋巴结组织与数字空间分析进行比较,产生了不同的分子表型。使用先进的分子技术对 COVID-19 快速尸检组织进行评估可以识别途径和效应物,在单细胞水平上绘制不同的受体图谱,并有助于剖析导致个体患者临床病程不同的差异。将这种方法扩展到更大的数据集将大大推进对 COVID-19 病理生理学背后机制的理解。